Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

scientific article published on October 2011

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0960-9776(11)70316-2
P698PubMed publication ID22015286

P2093author name stringIan Smith
Anastasia Constantinidou
P2860cites workHigh risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerQ24641848
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerQ27851549
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerQ29616112
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerQ29617440
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.Q34433731
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancerQ34496969
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.Q36901398
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.Q37123529
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyQ37163797
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancerQ43250044
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerQ43270036
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trialQ46736552
Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomasQ48111542
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.Q50773376
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].Q53048159
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.Q53243856
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast CancersQ59487524
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEMQ84592604
P921main subjectchemotherapyQ974135
P304page(s)S158-61
P577publication date2011-10-01
P1433published inThe BreastQ7719928
P1476titleIs there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
P478volume20 Suppl 3

Reverse relations

cites work (P2860)
Q44593682Complete Radiologic Response of Bulky Cerebral Metastases From Newly Diagnosed HER2-Positive Breast Cancer to Upfront Trastuzumab-Based Chemotherapy.
Q38132237Pertuzumab for the treatment of metastatic breast cancer
Q48294650Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study
Q28081124Treatment of early-stage HER2+ breast cancer-an evolving field

Search more.